Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. ADR
(NQ:
NBTX
)
5.300
-0.160 (-2.93%)
Streaming Delayed Price
Updated: 3:26 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
Next >
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
November 09, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
November 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
November 02, 2022
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
October 31, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 27, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
October 18, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
October 10, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
September 28, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
September 22, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
September 21, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
September 12, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix: Voting Rights and Shares Capital of the Company
September 08, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
September 07, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
September 06, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022
August 31, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX: Voting Rights and Shares Capital of the Company
August 09, 2022
From
Nanobiotix
Via
Business Wire
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont
July 13, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
June 09, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
June 05, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
June 02, 2022
From
Nanobiotix
Via
Business Wire
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
May 18, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Provides First Quarter Operational and Financial Update
May 18, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
May 17, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
May 11, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
May 10, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
May 04, 2022
From
NANOBIOTIX
Via
Business Wire
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
May 02, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
April 11, 2022
From
NANOBOTIX
Via
Business Wire
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
April 08, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
April 07, 2022
From
Nanobiotix
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.